Corcept Therapeutics Inc (CORT) 3.83 $CORT
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick"
announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst.
Corcept Therapeutics (CORT): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:39AM CDT
Corcept Therapeutics is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
US Oncology Research Joins Corcept Therapeutics' Phase I Breast Cancer Study
Marketwire - Wed Apr 02, 11:16AM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, and US Oncology Research, one of the largest community-based research programs in the United States, announced today that two sites affiliated with US Oncology Research will participate in Corcept's multi-center, Phase I clinical study of mifepristone in combination with chemotherapy drug eribulin (Halaven(R))(1) in patients with metastatic or locally advanced unresectable breast cancer.
Hot Stock: Corcept Therapeutics, Shares Gain 13.5% (CORT)
Comtex SmarTrend(R) - Fri Mar 28, 11:41AM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 13.5% to $4.38 on 1.2x average daily volume. Corcept Therapeutics has traded 641,000 shares thus far today, vs. average volume of 540,000 shares per day. The stock has outperformed the Dow (13.5% to the Dow's 0.7%) and outperformed the S&P 500 (13.5% to the S&P's 0.7%) during today's trading.
Will Corcept Therapeutics (CORT) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:45AM CDT
Will Corcept Therapeutics (CORT) Continue to Surge Higher?
Corcept Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Wed Mar 05, 8:02AM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2013.
Corcept Therapeutics Up 9.5%, Shares Break Through Resistance (CORT)
Comtex SmarTrend(R) - Tue Mar 04, 10:14AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 9.5% to $3.69 on 1.0x average daily volume. Corcept Therapeutics has traded 464,000 shares thus far today, vs. average volume of 457,000 shares per day. The stock has outperformed the Dow (9.5% to the Dow's 1.2%) and outperformed the S&P 500 (9.5% to the S&P's 1.3%) during today's trading.
TransCanada Files 2013 Annual Disclosure Documents
Marketwire Canada - Fri Feb 21, 3:26PM CST
TransCanada Corporation (TSX:TRP) (NYSE:TRP) (TransCanada) has today filed with Canadian securities authorities:
Traders Get Bullish on Shares of Corcept Therapeutics, Shares Up 6.9% (CORT)
Comtex SmarTrend(R) - Wed Feb 12, 11:41AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 6.9% to $3.25 on 2.8x average daily volume. Corcept Therapeutics has traded 1.3 million shares thus far today, vs. average volume of 473,000 shares per day. The stock has outperformed the Dow (6.9% to the Dow's -0.2%) and outperformed the S&P 500 (6.9% to the S&P's 0.0%) during today's trading.
Revenue Update from Corcept - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 3:50PM CST
Corcept expects to generate revenues of $4.1 million in the fourth quarter of 2013, above the Zacks Consensus Estimate of $3.0 million.
Why Corcept Therapeutics Incorporated Shares Dipped
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 31, 2:26PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Corcept Therapeutics , a biopharmaceutical...
Corcept Therapeutics Down 8.0%, Shares Slide into the Red (CORT)
Comtex SmarTrend(R) - Fri Jan 31, 10:11AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 8.0% to $3.43 on 1.2x average daily volume. Thus far today, Corcept Therapeutics has traded 578,000 shares, vs. average volume of 497,000 shares per day. The stock has underperformed the Dow (-8.0% to the Dow's -1.1%) and underperformed the S&P 500 (-8.0% to the S&P's -0.8%) during today's trading.
Corcept Therapeutics Announces Fourth Quarter, Full Year 2013 Revenue and Provides 2014 Outlook
Marketwire - Thu Jan 30, 3:06PM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT)
Corcept Therapeutics to Announce Fourth Quarter and Full Year Revenue and Corporate Update and Host Conference Call
Marketwire - Mon Jan 27, 7:30AM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full year 2013 revenue on January 30, 2014. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
The Simplest Non-Fad Diet Book You'll Ever Digest
PR Newswire - Thu Jan 23, 7:00AM CST
A poor diet speeds the effects of aging, derails metabolism and induces weight gain. "Maximized Metabolics," the latest book by New York Times best-selling author Dr. Ben Lerner gives readers the tools to maximize their metabolism and sidestep the early onset of aging.
3 Biggest Laggards in Health Care Last Week
George Budwell, The Motley Fool - Motley Fool - Mon Jan 20, 5:12PM CST
Health care stocks that drop rapidly can provide investors with compelling entry points, especially when the fall is due to an overreaction to a material event. With this theme in mind, here is my take on the three biggest laggards in the sector last...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Jan 18, 7:45AM CST
Have a less-than-stellar week at work? It could be worse. You could have owned shares in one of these three horrendous health-care stocks for the week. (My condolences to those with a bad week at work and in the market.) Gnashing of teeth ...
Investors look to Lighten Up on Shares of Corcept Therapeutics, Shares Down 12.0% (CORT)
Comtex SmarTrend(R) - Mon Jan 13, 10:14AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 12.0% to $3.30 on 1.4x average daily volume. Corcept Therapeutics has traded 616,000 shares thus far today, vs. average volume of 435,000 shares per day. The stock has underperformed the Dow (-12.0% to the Dow's -0.0%) and underperformed the S&P 500 (-12.0% to the S&P's -0.0%) during today's trading.
Downgrade Alert for Corcept Therapeutics (CORT)
Comtex SmarTrend(R) - Mon Jan 13, 7:00AM CST
Corcept Therapeutics (NASDAQ:CORT) was downgraded from Buy to Hold at Stifel today. The stock closed yesterday at $3.75 on volume of 291,000 shares, below average daily volume of 435,000. Based on a current price of $3.75, Corcept Therapeutics is currently 43.3% above its average consensus analyst price target of $2.12. The stock should find initial support at its 50-day moving average (MA) of $2.37 and further support at its 200-day MA of $1.92.
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick"
announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst. Corcept Therapeutics (CORT): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:39AM CDT
Corcept Therapeutics is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
US Oncology Research Joins Corcept Therapeutics' Phase I Breast Cancer Study
Marketwire - Wed Apr 02, 11:16AM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, and US Oncology Research, one of the largest community-based research programs in the United States, announced today that two sites affiliated with US Oncology Research will participate in Corcept's multi-center, Phase I clinical study of mifepristone in combination with chemotherapy drug eribulin (Halaven(R))(1) in patients with metastatic or locally advanced unresectable breast cancer.
Hot Stock: Corcept Therapeutics, Shares Gain 13.5% (CORT)
Comtex SmarTrend(R) - Fri Mar 28, 11:41AM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 13.5% to $4.38 on 1.2x average daily volume. Corcept Therapeutics has traded 641,000 shares thus far today, vs. average volume of 540,000 shares per day. The stock has outperformed the Dow (13.5% to the Dow's 0.7%) and outperformed the S&P 500 (13.5% to the S&P's 0.7%) during today's trading.
Will Corcept Therapeutics (CORT) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:45AM CDT
Will Corcept Therapeutics (CORT) Continue to Surge Higher?
Corcept Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Wed Mar 05, 8:02AM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2013.
Corcept Therapeutics Up 9.5%, Shares Break Through Resistance (CORT)
Comtex SmarTrend(R) - Tue Mar 04, 10:14AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 9.5% to $3.69 on 1.0x average daily volume. Corcept Therapeutics has traded 464,000 shares thus far today, vs. average volume of 457,000 shares per day. The stock has outperformed the Dow (9.5% to the Dow's 1.2%) and outperformed the S&P 500 (9.5% to the S&P's 1.3%) during today's trading.
TransCanada Files 2013 Annual Disclosure Documents
Marketwire Canada - Fri Feb 21, 3:26PM CST
TransCanada Corporation (TSX:TRP) (NYSE:TRP) (TransCanada) has today filed with Canadian securities authorities:
Traders Get Bullish on Shares of Corcept Therapeutics, Shares Up 6.9% (CORT)
Comtex SmarTrend(R) - Wed Feb 12, 11:41AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 6.9% to $3.25 on 2.8x average daily volume. Corcept Therapeutics has traded 1.3 million shares thus far today, vs. average volume of 473,000 shares per day. The stock has outperformed the Dow (6.9% to the Dow's -0.2%) and outperformed the S&P 500 (6.9% to the S&P's 0.0%) during today's trading.
Revenue Update from Corcept - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 3:50PM CST
Corcept expects to generate revenues of $4.1 million in the fourth quarter of 2013, above the Zacks Consensus Estimate of $3.0 million.
Why Corcept Therapeutics Incorporated Shares Dipped
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 31, 2:26PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Corcept Therapeutics , a biopharmaceutical...
Corcept Therapeutics Down 8.0%, Shares Slide into the Red (CORT)
Comtex SmarTrend(R) - Fri Jan 31, 10:11AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 8.0% to $3.43 on 1.2x average daily volume. Thus far today, Corcept Therapeutics has traded 578,000 shares, vs. average volume of 497,000 shares per day. The stock has underperformed the Dow (-8.0% to the Dow's -1.1%) and underperformed the S&P 500 (-8.0% to the S&P's -0.8%) during today's trading.
Corcept Therapeutics Announces Fourth Quarter, Full Year 2013 Revenue and Provides 2014 Outlook
Marketwire - Thu Jan 30, 3:06PM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT)
Corcept Therapeutics to Announce Fourth Quarter and Full Year Revenue and Corporate Update and Host Conference Call
Marketwire - Mon Jan 27, 7:30AM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full year 2013 revenue on January 30, 2014. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
The Simplest Non-Fad Diet Book You'll Ever Digest
PR Newswire - Thu Jan 23, 7:00AM CST
A poor diet speeds the effects of aging, derails metabolism and induces weight gain. "Maximized Metabolics," the latest book by New York Times best-selling author Dr. Ben Lerner gives readers the tools to maximize their metabolism and sidestep the early onset of aging.
3 Biggest Laggards in Health Care Last Week
George Budwell, The Motley Fool - Motley Fool - Mon Jan 20, 5:12PM CST
Health care stocks that drop rapidly can provide investors with compelling entry points, especially when the fall is due to an overreaction to a material event. With this theme in mind, here is my take on the three biggest laggards in the sector last...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Jan 18, 7:45AM CST
Have a less-than-stellar week at work? It could be worse. You could have owned shares in one of these three horrendous health-care stocks for the week. (My condolences to those with a bad week at work and in the market.) Gnashing of teeth ...
Investors look to Lighten Up on Shares of Corcept Therapeutics, Shares Down 12.0% (CORT)
Comtex SmarTrend(R) - Mon Jan 13, 10:14AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 12.0% to $3.30 on 1.4x average daily volume. Corcept Therapeutics has traded 616,000 shares thus far today, vs. average volume of 435,000 shares per day. The stock has underperformed the Dow (-12.0% to the Dow's -0.0%) and underperformed the S&P 500 (-12.0% to the S&P's -0.0%) during today's trading.
Downgrade Alert for Corcept Therapeutics (CORT)
Comtex SmarTrend(R) - Mon Jan 13, 7:00AM CST
Corcept Therapeutics (NASDAQ:CORT) was downgraded from Buy to Hold at Stifel today. The stock closed yesterday at $3.75 on volume of 291,000 shares, below average daily volume of 435,000. Based on a current price of $3.75, Corcept Therapeutics is currently 43.3% above its average consensus analyst price target of $2.12. The stock should find initial support at its 50-day moving average (MA) of $2.37 and further support at its 200-day MA of $1.92.
